Key result
VEGF drives NSCLC survival and tumor growth primarily via Neuropilin-1 receptor signaling.
Why the study?
The survival benefit of current VEGF-targeted therapies in NSCLC is limited and new targeted therapies are urgently needed due to underwhelming results with tyrosine kinase inhibitors.
Answers are grounded in this paper and cite their sources.
VEGF acts as an autocrine growth factor in NSCLC signaling through NP1, suggesting NP1 as a potential therapeutic target and biomarker for VEGF-targeted therapies.
BACKGROUND: The VEGF pathway has become an important therapeutic target in lung cancer, where VEGF has long been established as a potent pro-angiogenic growth factor expressed by many types of tumors. While Bevacizumab (Avastin) has proven successful in increasing the objective tumor response rate and in prolonging progression and overall survival in patients with NSCLC, the survival benefit is however relatively short and the majority of patients eventually relapse. The current use of tyrosine kinase inhibitors alone and in combination with chemotherapy has been underwhelming, highlighting an urgent need for new targeted therapies. In this study, we examined the mechanisms of VEGF-mediated survival in NSCLC cells and the role of the Neuropilin receptors in this process. METHODS: NSCLC cells were screened for expression of VEGF and its receptors. The effects of recombinant VEGF and its blockade on lung tumor cell proliferation and cell cycle were examined. Phosphorylation of Akt and Erk1/2 proteins was examined by high content analysis and confocal microscopy. The effects of silencing VEGF on cell proliferation and survival signaling were also assessed. A Neuropilin-1 stable-transfected cell line was generated. Cell growth characteristics in addition to pAkt and pErk1/2 signaling were studied in response to VEGF and its blockade. Tumor growth studies were carried out in nude mice following subcutaneous injection of NP1 over-expressing cells. RESULTS: Inhibition of the VEGF pathway with anti-VEGF and anti-VEGFR-2 antibodies or siRNA to VEGF, NP1 and NP2 resulted in growth inhibition of NP1 positive tumor cell lines associated with down-regulation of PI3K and MAPK kinase signaling. Stable transfection of NP1 negative cells with NP1 induced proliferation in vitro, which was further enhanced by exogenous VEGF. In vivo, NP1 over-expressing cells significantly increased tumor growth in xenografts compared to controls. CONCLUSIONS: Our data demonstrate that VEGF is an autocrine growth factor in NSCLC signaling, at least in part, through NP1. Targeting this VEGF receptor may offer potential as a novel therapeutic approach and also support the evaluation of the role of NP1 as a biomarker predicting sensitivity or resistance to VEGF and VEGFR-targeted therapies in the clinical arena.
No takes yet. Share an insight, caveat, or question.
Barr et al. (2015) studied Non-small cell lung cancer (preclinical) (n=16). VEGF pathway modulation (recombinant VEGF, neutralizing antibodies, siRNA, NP1 overexpression) vs. Control (untreated, IgG isotype, scrambled siRNA, empty vector) was evaluated on Tumor cell proliferation and in vivo tumor growth (p=<0.01). VEGF acts as an autocrine growth factor in non-small cell lung cancer, signaling primarily through the Neuropilin-1 receptor to promote cell survival and tumor growth.
Synapse has enriched 10 related papers. Consider them for comparative context: